See the latest news and media coverage for MedCap. We track all announcements, press releases, and industry mentions in real time, all in one place.
Acquirer and developer of life science companies
medcap.seLast updated
In short: MedCap posted 13% Q3 2026 sales growth and 30% adjusted EBITA growth at a 20.9% margin.
Net sales increased by 13 percent to SEK 566.7 million. The group shows high profitability and strong cash flow and expects continued value creation through future acquisitions.
Net sales reached 567 MSEK driven by strong performance across Assistive Tech, MedTech, and Specialty Pharma business units.
He will assume the position in the first quarter of 2027 and comes from Mölnlycke with extensive experience in healthcare and M&A.
Net sales rose 16% to SEK 606.3 million, with organic growth of 7%. The EBITA margin improved to 21.4%.
The acquisition company Medcap, active in life science, reports an EBITA result of 155 million SEK (90.1) for the third quarter of 2026.
Jul. 21 MedCap AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI Jul. 21 Medcap increased revenue and...
Linc-owned Medcap, which invests in Life science, had an adjusted EBITA result of 125 million kronor (97.5) in the second quarter of 2026.
MedCap AB ( (SE:MCAP)) has provided an announcement. MedCap AB has expanded its MedTech business area by acquiring Danish company Biopsafe ApS, which supplies an...
Track MedCap and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to MedCap and other trending companies.
